Abstract

Introduction: Oral metastases are rare and represent only 1% of malignant diseases of the oral cavity, but they are often associated with poor prognosis. The primary tumor is recognizable in most cases; however, in 27.6% of cases, metastasis is the first clinical manifestation. Observation: An 82-year-old consulted for the recent appearance of a 1-cm-wide gingival tumor on 46. Since this patient had metastatic clear cell renal cell carcinoma, oral metastasis was confirmed by histopathology. In the following weeks, other oral metastases appeared. Palliative radiotherapy was the chosen treatment option, but the patient died before he could benefit from it. Discussion: Multiple oral metastases are rare, and metastasis of renal origin is not the most frequently encountered. The metastatic dissemination pathway described is hematogenous or lymphatic. Diagnosis is often easy if the primary tumor is already identified, but is a challenge if it is not, because the lesion often has a nonspecific appearance. Different surgical, radiotherapeutic, and medical therapeutic options exist, but are often palliative. A new immunotherapy route is under development and looks promising in the treatment of renal cell carcinoma. Conclusions: Oral metastasis often has poor prognosis, and management of the lesion is problematic. However, current research suggests a therapeutic and prognostic improvement.

Highlights

  • Oral metastases are a rare phenomenon and represent only 1% of all forms of malignant diseases of the oral cavity

  • The primary tumor has previously been discovered, and the presence of metastases in the mouth is associated with a poor long-term prognosis

  • Renal cell carcinoma (RCC) accounts for about 3% of all malignant tumors found in adults

Read more

Summary

Introduction

Oral metastases are a rare phenomenon and represent only 1% of all forms of malignant diseases of the oral cavity. Renal cell carcinoma (RCC) accounts for about 3% of all malignant tumors found in adults It usually affects men aged 30–60 years [3] and can metastasize to any part of the body, with a 15% risk of metastasis to the head and neck area when the disease is disseminated and 1% risk when it is not. Given the patient’s poor general condition and on consultation with the oncologist, a simple monitoring of the evolution of the lesions was decided at first intention The patient died before any beneficial effect of the treatment could be seen

Discussion
Findings
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call